Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept Withdrawal and Retreatment in nr-ax SpA
NCT02509026Phase 4Completed
- Sponsor
- Pfizer
- Start
- Sep 2015
- Primary completion
- May 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 14
01
Overview
Phase 4, open-label, single-arm trial of etanercept in non-radiographic axial spondyloarthritis (nr-axSpA), sponsored by Pfizer. Primary endpoint: Percentage of Participants Who Experienced Flare Within 40 Weeks Following Withdrawal of 24 Weeks of Etanercept Treatment. Started Sep 2015; status: completed.
02
Drugs
etanercept
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NCT02509026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02509026.